<DOC>
	<DOCNO>NCT02609399</DOCNO>
	<brief_summary>This pilot study design demonstrate feasibility utilize Emergency Departments ( EDs ) primary site subject enrollment clinical trial evaluate influenza therapeutic , provide pilot data future clinical trial design planning . Primary Objective : To prospectively enroll high-risk subject laboratory-confirmed influenza randomize , open label study oral versus IV influenza therapeutic include symptom evaluation outcome assessment . Secondary Objective 1 : To identify influenza positive patient utilize previously establish triage-based assessment rapid test algorithm suspect influenza infection . Secondary Objective 2 : To retrospectively evaluate potentially eligible patient potential enrollment bias . Secondary Objective 3 : To create repository residual nasopharyngeal sample collect ED patient suspect influenza illness .</brief_summary>
	<brief_title>ED Influenza Therapeutic Pilot Study : Oseltamivir vs. Peramivir</brief_title>
	<detailed_description>Title : A Pilot Randomized Controlled Trial Feasibility Enrolling Subjects Influenza Therapeutic Trials Administering Influenza Antivirals Emergency Department High Risk Subjects Population : Adults present emergency department ( ED ) laboratory confirm influenza meet Centers Disease Control Prevention ( CDC ) criteria antiviral treatment Informed consent : Written inform consent Number Sites : 2 - large , urban , academically-affiliated , US EDs Study Duration : September 2015 - September 2018 Subject Participation Duration : 4 week Description Agent Intervention : Subjects randomize either oral ( oseltamivir ) intravenous ( IV ) ( peramivir ) antiviral treatment . Description Study Design : This open-label randomized control clinical trial subject influenza randomize either oral ( oseltamivir ) IV ( peramivir ) antiviral treatment . Estimated Time Complete Enrollment : Subject enrollment occur two influenza season ( November 2015 - April 2017 ) longer , co-principal investigator ' ( Co-PIs ' ) discretion , base influenza prevalence .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<mesh_term>Peramivir</mesh_term>
	<criteria>Eligible patient include patient present emergency department ( ED ) November April influenza season , later , CoPIs ' discretion , base influenza prevalence , follow criterion : 1 . 18 year age old 2 . Laboratory confirm positive influenza test associate current ED visit 3 . Symptoms acute respiratory illness ≤4 day ( 96 hour ) 4 . Meets CDC criterion antiviral treatment For purpose study , acute respiratory illness define presence follow symptom : new increase cough , new increase shortness breath , change sputum production ( adults 65 year old ) , sinus pain , nasal congestion , rhinorrhea , sore throat , subjective fever report time triage document fever ( define ≥ 38 degree Celsius ) . CDC criterion influenza antiviral treatment define : age 65 year old old , pregnant less two week postpartum , American Indian Alaska native , morbid obesity ( BMI ≥40 ) , current resident nursing home chroniccare facility , chronic pulmonary disease , cardiovascular disease ( except hypertension alone ) , renal disease , hepatic disease , hematologic disease , metabolic disorder , neurologic neurodevelopment condition , immunosuppression ( include cause medication HIV infection ) , admit inpatient observation unit , clinical diagnosis pneumonia ( ED physician ) . 1 . Does speak understand English ( English Spanish ) 2 . Unable unwilling provide inform consent 3 . Previously enrol study current influenza season 4 . Unable take oral medication 5 . Unable comply plan study procedure include availability followup willingness complete study diary selfassessment 6 . Use neuraminidase inhibitor within past seven day 7 . Known allergic reaction neuraminidase inhibitor 8 . Pregnant breastfeed 9 . Endstage renal disease , define 9a . Currently undergoing dialysis ( either hemo peritoneal ) ; 9b . Creatinine clearance ( CrCl ) &lt; 10 mL/min . 10 . Endstage liver disease , determine treat ED provider 11 . Glucose6phosphate dehydrogenase ( G6PD ) deficiency patient report 12 . Immunodeficiency , define : 12a . Solid organ transplant patient receive immunosuppression ; 12b . Hematopoietic stem cell transplant patient within 12 month transplant ongoing immunosuppression ; 12c . Oncology patient chemotherapy within past 30 day ; 12d . Current treatment steroid equivalent 10 mg prednisone per day great two week ; 12e . Rheumatologic patient receive immunosuppressive therapy ; 12f . HIV patient meet one follow criterion : 12fi . Have CD4 cell count &lt; 200 cells/mm3 within past 3 month ; 12fii . Not actively receive highly active antiretroviral therapy ( HAART ) ; 12fiii . Have absolute lymphocyte count &lt; 1.0 x 103 cells/μL conduct current ED visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Antiviral treatment</keyword>
	<keyword>Emergency department</keyword>
	<keyword>Influenza therapeutic</keyword>
	<keyword>Rapid influenza test</keyword>
</DOC>